A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

被引：379
|
作者：
Cobleigh, MA
Langmuir, VK
Sledge, GW
Miller, KD
Haney, L
Novotny, WF
Reimann, JD
Vassel, A
机构：
[1] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
[2] Genentech Inc, San Francisco, CA USA
[3] Indiana Univ, Indianapolis, IN 46204 USA
来源：
SEMINARS IN ONCOLOGY | 2003年 / 30卷 / 05期
关键词：
D O I：
10.1053/j.seminoncol.2003.08.013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：117 / 124
页数：8
相关论文
共 50 条
  • [21] Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with resistant/refractory ovarian cancer
    Smit, W. M.
    Sufliarsky, J.
    Spanik, S.
    Wagnerova, M.
    Kaye, S.
    Oza, A. M.
    Gore, M.
    Williams, K. J.
    Johri, A.
    Huinink, W. W. ten Bokkel
    EJC SUPPLEMENTS, 2005, 3 (02): : 261 - 262
  • [22] Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer
    Saunders, MP
    Hogg, M
    Carrington, B
    Sjursen, AM
    Allen, J
    Beech, J
    Swindell, R
    Valle, JW
    BRITISH JOURNAL OF CANCER, 2004, 91 (08) : 1447 - 1452
  • [23] Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer
    M P Saunders
    M Hogg
    B Carrington
    A-M Sjursen
    J Allen
    J Beech
    R Swindell
    J W Valle
    British Journal of Cancer, 2004, 91 : 1447 - 1452
  • [24] A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
    Dickler, Maura N.
    Rugo, Hope S.
    Eberle, CareyA.
    Brog, Edi
    Caravelli, James F.
    Panageas, Katherine S.
    Boyd, Jeff
    Yeh, Benjamim
    Lake, Diana E.
    Dang, Chau T.
    Gilewski, Teresa A.
    Bromberg, Jacqueline F.
    Seidman, Andrew D.
    D'Andrea, Gabriella M.
    Moasser, Mark M.
    Melisko, Michele
    Park, John W.
    Dancey, Janet
    Norton, Larry
    Hudis, Clifford A.
    CLINICAL CANCER RESEARCH, 2008, 14 (23) : 7878 - 7883
  • [25] Perioperative administration of desmopressin (dDAVP) in breast cancer patients: A phase II dose-escalation study
    Weinberg, Ruth S.
    Grecco, Marcelo O.
    Ferro, Gimena S.
    Seigelshifer, Debora
    Perroni, Nancy V.
    Terrier, Francisco J.
    Luceros, Analia Sanchez
    Domenichini, Enzo
    Guthmann, Marcelo D.
    Di Leo, Daniela
    Spitzer, Eduardo
    Ciccia, Graciela N.
    Torbidoni, Ana V.
    Garona, Juan
    Pifano, Marina
    Ripoll, Giselle V.
    Gomez, Roberto E.
    Alonso, Daniel F.
    CANCER RESEARCH, 2015, 75
  • [26] Phase I dose-escalation trial of tremelimumab in combination with bicalutamide in patients with recurrent prostate cancer
    Lang, J. M.
    Staab, M. J.
    Liu, G.
    Wilding, G.
    McNeel, D. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [27] A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients
    Zhou, Xinna
    Yu, Jing
    Wang, Wenmiao
    Song, Guohong
    Wang, Xiaoli
    Ren, Jun
    Di, Lijun
    Wang, Xinghe
    SPRINGERPLUS, 2015, 4 : 1 - 6
  • [28] A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis
    Burton, J. M.
    Kimball, S.
    Vieth, R.
    Bar-Or, A.
    Dosch, H. -M.
    Cheung, R.
    Gagne, D.
    D'Souza, C.
    Ursell, M.
    O'Connor, P.
    NEUROLOGY, 2010, 74 (23) : 1852 - 1859
  • [29] Pegylated liposomal doxorubicin in previously treated patients with metastatic breast cancer - a large multicenter phase II trial
    Al-Batran, SE
    Bischoff, J
    von Minckwitz, G
    Atmaca, A
    Kleeberg, U
    Meuthen, I
    Morack, G
    Lerbs, W
    Hccker, D
    Jager, E
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S280 - S280
  • [30] Oral metronomic administration of cyclophosphamide and vinorelbine in previously treated patients with metastatic breast cancer: Phase II trial
    Pluma Jimenez, M. A.
    Perez, M.
    Bautista Aragon, Y. L.
    Villalobos, R.
    Rivera, S.
    Ortiz, K.
    Avila, G. G.
    Silva, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345